Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    (A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

    Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.

  • SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

    Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

  • Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

    Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

  • UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

    Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

  • Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NGfmWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMECwN|A{KM7:TR?= M2rNZnNCVkeHUh?=
IST-MEL1 M2XFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvuWndKSzVyPUCuNFAxPDB5IN88US=> M1K2b3NCVkeHUh?=
NCI-SNU-1 M1vwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonOTWM2OD1yLkCwNlA4KM7:TR?= Mom0V2FPT0WU
FADU NHH0cWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfETG1KSzVyPUCuNFAzODlizszN M4fSV3NCVkeHUh?=
C32 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCyUWJyUUN3ME2wMlAxOzB2IN88US=> M4LzZXNCVkeHUh?=
D-566MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXiSVNKSzVyPUCuNFA{QSEQvF2= MXrTRW5ITVJ?
LXF-289 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jWc2lEPTB;MD6wNFQyQSEQvF2= MoC2V2FPT0WU
HGC-27 NWKxdVNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm5TWM2OD1yLkCwOVEh|ryP MlXMV2FPT0WU
RPMI-7951 M1PIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEC3NVch|ryP NEn1cotUSU6JRWK=
HSC-3 NXLNc3ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX3WYhKSzVyPUCuNFA6OjlizszN MnOzV2FPT0WU
MIA-PaCa-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvZ[YYxUUN3ME2wMlAyODB7IN88US=> MlLWV2FPT0WU
KS-1 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMEGzOVUh|ryP NUHLW3IyW0GQR1XS
CAL-51 NFXS[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEG0NFUh|ryP MV\TRW5ITVJ?
MDA-MB-361 M{fMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULVNFl2UUN3ME2wMlAyPDl3IN88US=> NIridWFUSU6JRWK=
TI-73 M{C3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTrTWM2OD1yLkCxO|k3KM7:TR?= M1HNZ3NCVkeHUh?=
AGS NUW5cXF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zkZWlEPTB;MD6wNVk{QCEQvF2= NIHifXZUSU6JRWK=
NCI-H460 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTYVIdxUUN3ME2wMlAyQTd2IN88US=> M1z5d3NCVkeHUh?=
A204 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjrSYd{UUN3ME2wMlAzOjR7IN88US=> NFfFXYRUSU6JRWK=
CHL-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm1TWM2OD1yLkCyNlUyKM7:TR?= M2nQO3NCVkeHUh?=
DU-4475 NHf4VopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LOSmlEPTB;MD6wNlI3OSEQvF2= NVjP[llEW0GQR1XS
CGTH-W-1 NX:yNFRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jYSGlEPTB;MD6wNlM1QSEQvF2= MXXTRW5ITVJ?
HCC2218 M4Xj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\FeVNRUUN3ME2wMlAzPDl2IN88US=> MWnTRW5ITVJ?
A2780 NYPuWW9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwMEK1N|Eh|ryP M{jYfXNCVkeHUh?=
NCI-H720 NFPoTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvTb3BRUUN3ME2wMlAzPTR4IN88US=> M2jB[3NCVkeHUh?=
NCI-N87 NFHkVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\oTWM2OD1yLkCyOVk{KM7:TR?= M1\kb3NCVkeHUh?=
CHP-212 NIi4RnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrIUGdKSzVyPUCuNFI3OjhizszN MXvTRW5ITVJ?
NCI-H23 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGzTWM2OD1yLkCyOlY2KM7:TR?= NWi1PJBbW0GQR1XS
D-263MG MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEK3PFYh|ryP M3vqfXNCVkeHUh?=
ME-180 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7GcmFKSzVyPUCuNFI5QTFizszN NEHNRlBUSU6JRWK=
SW982 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LHTWlEPTB;MD6wNlk6QSEQvF2= MXfTRW5ITVJ?
OE19 M1PBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLqfGJbUUN3ME2wMlA{ODd5IN88US=> NX7VVpU6W0GQR1XS
SK-LU-1 M3S0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\5SWlEPTB;MD6wN|A5OiEQvF2= MULTRW5ITVJ?
H4 NX7TR4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvJdnJKSzVyPUCuNFMxQSEQvF2= M4jWdnNCVkeHUh?=
HT-144 NX3LZVhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzhTpN2UUN3ME2wMlA{ODl|IN88US=> NH60NGVUSU6JRWK=
SK-UT-1 NV7NUIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITn[29KSzVyPUCuNFMyPzhizszN MWrTRW5ITVJ?
D-336MG NXy5RVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEOzNFkh|ryP MVLTRW5ITVJ?
MDA-MB-175-VII NWW3NnFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z1emlEPTB;MD6wN|M2PCEQvF2= NFX0TYpUSU6JRWK=
GAMG MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXNS5NKSzVyPUCuNFM1OzVizszN NGrCZm9USU6JRWK=
CP50-MEL-B NWfMXWY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O1S2lEPTB;MD6wN|Q2KM7:TR?= MmjmV2FPT0WU
OVCAR-5 NYrv[mNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfHcFBoUUN3ME2wMlA{PDhizszN MWrTRW5ITVJ?
SK-MES-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHGTWM2OD1yLkCzOlA3KM7:TR?= MVPTRW5ITVJ?
VM-CUB-1 M135b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfXTWRKSzVyPUCuNFM3PTdizszN NYPSdmFTW0GQR1XS
WM-115 NWXO[GZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TNPGlEPTB;MD6wN|c3OiEQvF2= Ml3rV2FPT0WU
DSH1 M4j3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMEO4NFch|ryP MlK1V2FPT0WU
Becker NEOwTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jZVmlEPTB;MD6wN|g5PSEQvF2= Ml;1V2FPT0WU
SW962 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nZfGlEPTB;MD6wN|k1PSEQvF2= MWTTRW5ITVJ?
TYK-nu NWLj[pN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrObVJKSzVyPUCuNFM6QDVizszN Mo\FV2FPT0WU
HO-1-N-1 NYHYbohMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIexZ|JKSzVyPUCuNFQxOjFizszN NI\DU4lUSU6JRWK=
T98G M1PHUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMESxNFMh|ryP M2\VOXNCVkeHUh?=
ACN NVPj[ZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzVcFlrUUN3ME2wMlA1OTZ{IN88US=> NXnEOIVbW0GQR1XS
SW780 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDidVlKSzVyPUCuNFQzODNizszN M3\RcnNCVkeHUh?=
Detroit562 NF7IVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S3eGlEPTB;MD6wOFI{QSEQvF2= NX:yOG0{W0GQR1XS
BB49-HNC MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[3NWlEPTB;MD6wOFI1OyEQvF2= MonBV2FPT0WU
HN MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\QcGlEPTB;MD6wOFI4OiEQvF2= NHXXOXNUSU6JRWK=
H9 NGHSdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMESzO|Eh|ryP M2fvVnNCVkeHUh?=
VA-ES-BJ M4PMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnCbmhGUUN3ME2wMlA1PDR5IN88US=> MVHTRW5ITVJ?
MEL-JUSO MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Pmb2lEPTB;MD6wOFQ4PSEQvF2= MXLTRW5ITVJ?
BT-474 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7WUFZKUUN3ME2wMlA1PSEQvF2= NYm1XVJDW0GQR1XS
CaR-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPzTWM2OD1yLkC0OVQ6KM7:TR?= NHPw[4NUSU6JRWK=
PSN1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMES2NFMh|ryP NFLocI1USU6JRWK=
KYSE-510 M4P5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL4TWM2OD1yLkC0OlQ6KM7:TR?= NX;DT3NEW0GQR1XS
KP-4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XmTmlEPTB;MD6wOFc2OyEQvF2= NXnWSHRHW0GQR1XS
KYSE-410 M16yfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMES3O|Ih|ryP NVHSSWpHW0GQR1XS
G-402 NWTpRVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe2cGpkUUN3ME2wMlA1Pzh7IN88US=> MYjTRW5ITVJ?
DOK Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMES5NFIh|ryP NV[3fHFNW0GQR1XS
COR-L88 NFvXVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMES5NVIh|ryP NHrlPXRUSU6JRWK=
SKG-IIIa M1fiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC4TWM2OD1yLkC0PVg3KM7:TR?= MVnTRW5ITVJ?
AN3-CA MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jER2lEPTB;MD6wOUDPxE1? NUPZc3pJW0GQR1XS
SW48 M2\p[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fNVGlEPTB;MD6wOVA{QSEQvF2= M{XiO3NCVkeHUh?=
YKG-1 NEDKTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3NNHA5UUN3ME2wMlA2ODdzIN88US=> NWHWZ|VLW0GQR1XS
KYSE-150 M1KxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXmeG1zUUN3ME2wMlA2OjN3IN88US=> M1\5RnNCVkeHUh?=
HuO-3N1 NWf0OYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXZbW1jUUN3ME2wMlA2OjN5IN88US=> MlXEV2FPT0WU
LB1047-RCC Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrJTWM2OD1yLkC1Nlk3KM7:TR?= NUnURZJvW0GQR1XS
NCI-H2030 NGr6eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X0RWlEPTB;MD6wOVQyPCEQvF2= MXXTRW5ITVJ?
YH-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEW3NlIh|ryP MkXHV2FPT0WU
5637 NVLhTVF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPoTWM2OD1yLkC1O|Qh|ryP Ml6yV2FPT0WU
LOXIMVI MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMEW4O|Ih|ryP NIHoVFlUSU6JRWK=
GT3TKB Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTqemVsUUN3ME2wMlA2QTR{IN88US=> NVrTNFRPW0GQR1XS
TCCSUP Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH32b2tKSzVyPUCuNFU6PjRizszN MU\TRW5ITVJ?
EPLC-272H MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLzTWM2OD1yLkC2NlA2KM7:TR?= M1\3b3NCVkeHUh?=
LU-99A NYDS[mJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTKTWM2OD1yLkC2NlM4KM7:TR?= NGfDTZlUSU6JRWK=
NCI-H1755 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXlb3RjUUN3ME2wMlA3OzRzIN88US=> Mo\xV2FPT0WU
KM12 NI\rNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\Q[45KSzVyPUCuNFY{PDhizszN MUfTRW5ITVJ?
SF295 NYnWPJNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPVbFJCUUN3ME2wMlA3PDV{IN88US=> NGPJfItUSU6JRWK=
MZ2-MEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofFTWM2OD1yLkC2OVU{KM7:TR?= NY\qOVA{W0GQR1XS
HEC-1 NUKxWHpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nXVGlEPTB;MD6wOlU5QCEQvF2= MVHTRW5ITVJ?
SW684 NH;qSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnpeHlSUUN3ME2wMlA3PTlzIN88US=> MV3TRW5ITVJ?
SF539 NIK0dI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTuOodGUUN3ME2wMlA3PjhzIN88US=> MXXTRW5ITVJ?
GMS-10 NYnBWmYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL6WoVKSzVyPUCuNFY3QTlizszN NWD6T|dnW0GQR1XS
MV-4-11 M13P[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnzRYRwUUN3ME2wMlA3QDB|IN88US=> NHOz[2dUSU6JRWK=
HT-29 M37qN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnVS3dYUUN3ME2wMlA3QTF7IN88US=> NFzqVYNUSU6JRWK=
23132-87 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XRe2lEPTB;MD6wOlk2KM7:TR?= NES0dYNUSU6JRWK=
SW620 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17rXGlEPTB;MD6wO|AzPiEQvF2= NXPUfWZKW0GQR1XS
HCC1806 M{j4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEexN|Eh|ryP MmH4V2FPT0WU
Hs-578-T NXe0WnhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjIbJBUUUN3ME2wMlA4OjB6IN88US=> MlzpV2FPT0WU
A2058 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[0U3pKSzVyPUCuNFczOjhizszN NX\IeWJYW0GQR1XS
MEL-HO M1jyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXkRlhKSzVyPUCuNFczPTVizszN M3TtZnNCVkeHUh?=
HCC2998 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTkUG9KSzVyPUCuNFc{PDdizszN NGrrO29USU6JRWK=
HuO9 M3exW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEe1PFkh|ryP Ml\tV2FPT0WU
CAL-39 NV[3[JY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r2eWlEPTB;MD6wO|c3PiEQvF2= NIfoOmZUSU6JRWK=
M14 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqzVJZuUUN3ME2wMlA4QTF|IN88US=> NHrJVoxUSU6JRWK=
BFTC-909 MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvYSpdWUUN3ME2wMlA4QTZ7IN88US=> Mmm4V2FPT0WU
TE-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlniTWM2OD1yLkC3PVk3KM7:TR?= NFLlb4pUSU6JRWK=
TGBC1TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEiwOFMh|ryP NF;CeGpUSU6JRWK=
L-363 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fEN2lEPTB;MD6wPFIxPiEQvF2= M2LkbXNCVkeHUh?=
A431 NYXBfYpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zFdGlEPTB;MD6wPFIyKM7:TR?= M3zidnNCVkeHUh?=
MKN45 NH\NS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LocWlEPTB;MD6wPFIyQSEQvF2= M3jH[3NCVkeHUh?=
HT-1080 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\GZ5VtUUN3ME2wMlA5PDN7IN88US=> NFrndnRUSU6JRWK=
OVCAR-8 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HkfWlEPTB;MD6wPFYzOiEQvF2= MkXCV2FPT0WU
LCLC-97TM1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M134Z2lEPTB;MD6wPFczQCEQvF2= NVXYNGNOW0GQR1XS
M059J MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml71TWM2OD1yLkC5NFI4KM7:TR?= NFTScYpUSU6JRWK=
SK-MEL-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr1TGhCUUN3ME2wMlA6ODZizszN NXz4Wm1EW0GQR1XS
TE-1 NVzYTJp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\NN2lEPTB;MD6wPVIxPCEQvF2= NICzOoJUSU6JRWK=
KYSE-180 NUHWZ49LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMEmyOlIh|ryP NFHIR4ZUSU6JRWK=
D-247MG NH3MV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:1OWlEPTB;MD6wPVQ2PSEQvF2= MXvTRW5ITVJ?
8-MG-BA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW5SZBkUUN3ME2wMlA6PDd{IN88US=> NGD0NG1USU6JRWK=
NCI-H1792 NGjzbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH2TWM2OD1yLkC5OlE5KM7:TR?= MoHuV2FPT0WU
MCF7 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTJWFFpUUN3ME2wMlA6Pjd5IN88US=> MU\TRW5ITVJ?
NCI-H2122 NEjYOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7ZdWlIUUN3ME2wMlA6PzR3IN88US=> MnXLV2FPT0WU
EFO-27 NHPCRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITlcYxKSzVyPUCuNFk6QTdizszN NVOxZWpXW0GQR1XS
LB2241-RCC M3T2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG1TWM2OD1yLkGwNFU1KM7:TR?= M3TTNnNCVkeHUh?=
SN12C NG\XcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInoSGhKSzVyPUCuNVAyODdizszN M1HK[HNCVkeHUh?=
A498 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjQTWM2OD1yLkGwNVgh|ryP MX7TRW5ITVJ?
PANC-03-27 NHvvZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fOeGlEPTB;MD6xNFI5PiEQvF2= MnK3V2FPT0WU
NCI-H1581 NX:0OXBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfBXmgzUUN3ME2wMlExOjlizszN NHHHT2tUSU6JRWK=
U-87-MG MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXTdJlKSzVyPUCuNVA{ODdizszN MX;TRW5ITVJ?
G-401 M3Lse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\PXpA3UUN3ME2wMlExOzV|IN88US=> M1HYU3NCVkeHUh?=
SiHa NX7yfXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\TXoN{UUN3ME2wMlExPDh4IN88US=> NV;weGZFW0GQR1XS
U251 NVjNXnl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTV[XhVUUN3ME2wMlExPTJ3IN88US=> NHn0eHhUSU6JRWK=
MMAC-SF MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqwTnFRUUN3ME2wMlExPTNzIN88US=> NX:4OFJZW0GQR1XS
BB65-RCC MoPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;oWnVkUUN3ME2wMlExPTV2IN88US=> M1jFRXNCVkeHUh?=
NKM-1 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMUC2OlYh|ryP NFLhdpBUSU6JRWK=
HD-MY-Z MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMUC4O|Mh|ryP MULTRW5ITVJ?
TGBC11TKB Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LmPGlEPTB;MD6xNFkxOyEQvF2= NGX4WmdUSU6JRWK=
COLO-679 NETOVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PYUGlEPTB;MD6xNVIyOSEQvF2= MlnOV2FPT0WU
TE-8 Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Tb3BKSzVyPUCuNVEzPjRizszN M{[0O3NCVkeHUh?=
SK-MEL-28 NFXLZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vjZ2lEPTB;MD6xNVMzOSEQvF2= MlWyV2FPT0WU
SH-4 NV\oVJM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMUGzOVYh|ryP NVHk[FI4W0GQR1XS
KALS-1 NVrsVZRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;0TWM2OD1yLkGxN|k{KM7:TR?= M1GzXHNCVkeHUh?=
RKO NXzwPVFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe2[WFUUUN3ME2wMlEyPzZ2IN88US=> MkPZV2FPT0WU
OMC-1 NGPu[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjaTWM2OD1yLkGxO|k4KM7:TR?= M4HWSHNCVkeHUh?=
BT-549 NHO0V49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13nOGlEPTB;MD6xNVc6QSEQvF2= MojNV2FPT0WU
NCI-H28 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUG4NVch|ryP NUn5d3FWW0GQR1XS
RXF393 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHRZnJKSzVyPUCuNVE6QDJizszN MlPvV2FPT0WU
COLO-829 M17JUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHQTWM2OD1yLkGyNFA2KM7:TR?= M3HzfHNCVkeHUh?=
HMV-II NELDU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuwbVFKSzVyPUCuNVIxOiEQvF2= M4\kPHNCVkeHUh?=
SW1990 NX[0VFRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMUKxOVch|ryP NXXyN|ZrW0GQR1XS
NCI-H1437 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLZTWM2OD1yLkGyNVU4KM7:TR?= NXrlRZFYW0GQR1XS
SNB75 NGCyUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMUKxOlkh|ryP MoHDV2FPT0WU
EW-3 NET6O25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMUK2OlEh|ryP M4T1RXNCVkeHUh?=
SAS M1:5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMUK2PUDPxE1? MULTRW5ITVJ?
NCI-H1666 NGe2OotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fyfWlEPTB;MD6xNlc4PCEQvF2= NED4WVNUSU6JRWK=
A375 M3\W[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mwWWlEPTB;MD6xNlc4QCEQvF2= Mk\zV2FPT0WU
CAMA-1 Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTUTWM2OD1yLkGyPVI1KM7:TR?= MmDHV2FPT0WU
HuP-T4 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW1U4JKSzVyPUCuNVI6PDNizszN NVvoe3V[W0GQR1XS
NCI-H292 NXXQNGV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\qTWM2OD1yLkGzNVEh|ryP MYHTRW5ITVJ?
PC-14 NX\iOYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUOyNVEh|ryP MmO3V2FPT0WU
BPH-1 NIfz[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfifZZKUUN3ME2wMlE{PDFizszN MoTGV2FPT0WU
GAK NWXRfmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HZUGlEPTB;MD6xN|U3PyEQvF2= MV;TRW5ITVJ?
VMRC-RCZ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFexdmNKSzVyPUCuNVM4PjJizszN NXfGWXZNW0GQR1XS
SK-MEL-24 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M322PGlEPTB;MD6xN|g4KM7:TR?= MkTEV2FPT0WU
LB831-BLC NXT6[41sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMUO4PFMh|ryP NFf6UHJUSU6JRWK=
NCI-H2452 Mo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT0TWM2OD1yLkGzPVU3KM7:TR?= MYjTRW5ITVJ?
RT-112 NXH0RodMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDnUJRKSzVyPUCuNVQxOzVizszN NYO4WWZmW0GQR1XS
GP5d M3\OT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;NZmU6UUN3ME2wMlE1OTB2IN88US=> NUj3VIZ7W0GQR1XS
LC-2-ad Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHLVWhKSzVyPUCuNVQyOjFizszN MojsV2FPT0WU
MPP-89 M33Hdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPs[JU5UUN3ME2wMlE1OTJ3IN88US=> MXTTRW5ITVJ?
NUGC-3 NFyzOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPVTWM2OD1yLkG0OFc5KM7:TR?= M2\rVnNCVkeHUh?=
GI-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPaTWM2OD1yLkG0OVU5KM7:TR?= NXnmVItZW0GQR1XS
HCC1419 M3\afWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnLTWM2OD1yLkG0OVc3KM7:TR?= MVfTRW5ITVJ?
SW1573 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzzVmo1UUN3ME2wMlE1PzV6IN88US=> M2T3NXNCVkeHUh?=
NCI-H2347 NUD0VINVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TkcWlEPTB;MD6xOFg{QSEQvF2= M{\lR3NCVkeHUh?=
Mewo NHnG[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoO0TWM2OD1yLkG0PFg6KM7:TR?= NF34VIFUSU6JRWK=
639-V MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMUWwNVMh|ryP MVrTRW5ITVJ?
AsPC-1 MmjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLye|BSUUN3ME2wMlE2OjJ3IN88US=> Ml3tV2FPT0WU
NCI-H1648 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nEXmlEPTB;MD6xOVI{OiEQvF2= Mo\uV2FPT0WU
786-0 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrwclFKSzVyPUCuNVU{QDFizszN MV;TRW5ITVJ?
ETK-1 NEWzOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnwXmdKSzVyPUCuNVU6KM7:TR?= MVTTRW5ITVJ?
BxPC-3 MmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTzTWM2OD1yLkG1PVY3KM7:TR?= MljkV2FPT0WU
CAL-62 NWLVe5dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv1ZpVKSzVyPUCuNVYyPjlizszN M4nofXNCVkeHUh?=
HCC1937 NFXaW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvBTWM2OD1yLkG2Nlc2KM7:TR?= NEHXNZJUSU6JRWK=
NCI-H1299 NV7VO3NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG1RXZGUUN3ME2wMlE3Ojh3IN88US=> M{LMVHNCVkeHUh?=
SW1088 NHSxWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHsTWM2OD1yLkG2OFE{KM7:TR?= MVPTRW5ITVJ?
FTC-133 M1fGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T5WWlEPTB;MD6xOlU1KM7:TR?= Ml:wV2FPT0WU
OC-314 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7BXXdUUUN3ME2wMlE3PjlizszN MorvV2FPT0WU
SCC-9 NXrsNVlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzyXGRRUUN3ME2wMlE3PzF4IN88US=> NFjySGVUSU6JRWK=
HT-1376 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1R2ZKSzVyPUCuNVY6OzZizszN MXnTRW5ITVJ?
U-2-OS NInCVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP1VHdsUUN3ME2wMlE4OTd|IN88US=> NEfIb5dUSU6JRWK=
COLO-824 MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMUeyPVQh|ryP MUfTRW5ITVJ?
BB30-HNC NY\iV4FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPGTWM2OD1yLkG3N|Mh|ryP Ml;LV2FPT0WU
NCI-H2087 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn4cGRSUUN3ME2wMlE4OzZ6IN88US=> MkLJV2FPT0WU
NCI-H2170 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3vTWM2OD1yLkG3OVM3KM7:TR?= NGm3O3hUSU6JRWK=
SK-OV-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXm[G5XUUN3ME2wMlE4PTdzIN88US=> NVXndIR2W0GQR1XS
MZ7-mel MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrPUnZKSzVyPUCuNVc3PDlizszN NXP6UYF{W0GQR1XS
NCI-H650 NHfjVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTlTWM2OD1yLkG3OlgzKM7:TR?= NH\FZXBUSU6JRWK=
KOSC-2 NYnwfVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLhTWM2OD1yLkG3O|M1KM7:TR?= M{XsPHNCVkeHUh?=
SCC-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTPZldKSzVyPUCuNVc4PzdizszN MmHvV2FPT0WU
MDA-MB-157 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD2N5lPUUN3ME2wMlE5ODh{IN88US=> NH:wdopUSU6JRWK=
KYSE-520 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13uSWlEPTB;MD6xPFIh|ryP MV\TRW5ITVJ?
LK-2 NWX2fJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLSTmtnUUN3ME2wMlE5OzB|IN88US=> M1\nWnNCVkeHUh?=
KNS-81-FD NFTtWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMUizPVQh|ryP NXXNclhJW0GQR1XS
IGROV-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;CTWM2OD1yLkG4OFQ{KM7:TR?= NXrvcFV7W0GQR1XS
DEL M17JV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPaTWM2OD1yLkG4OFUh|ryP MnL6V2FPT0WU
NCI-H1395 NFPBclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf0XmFKSzVyPUCuNVg3QDJizszN NXX2[ZhlW0GQR1XS
JEG-3 NFnR[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHFUpVVUUN3ME2wMlE5PzB3IN88US=> MWTTRW5ITVJ?
BCPAP M1LJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELMcmZKSzVyPUCuNVg5PzJizszN MUjTRW5ITVJ?
CAL-27 M1TpZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjkOHlKSzVyPUCuNVkxOjJizszN MYjTRW5ITVJ?
RD NVnrXJNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvOeWZFUUN3ME2wMlE6OTF|IN88US=> NYjmUFdpW0GQR1XS
RVH-421 M2LOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\CXYtvUUN3ME2wMlE6OTF4IN88US=> MoG3V2FPT0WU
Capan-2 Mly0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TTdGlEPTB;MD6xPVI2PiEQvF2= NY[2eFBjW0GQR1XS
COLO-680N MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPZTWM2OD1yLkG5N|Y1KM7:TR?= NXnlU|ZPW0GQR1XS
NCI-H1650 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLNTWM2OD1yLkKwNFU4KM7:TR?= M{[5eHNCVkeHUh?=
SBC-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC5ZYlMUUN3ME2wMlIxOTF6IN88US=> NITsU2tUSU6JRWK=
U031 NHnqTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMkC1OFch|ryP MXHTRW5ITVJ?
S-117 NWP1c4V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPpTWM2OD1yLkKwOVY1KM7:TR?= NFvleWRUSU6JRWK=
DoTc2-4510 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLYO5lXUUN3ME2wMlIxPzZ7IN88US=> NWfINGpbW0GQR1XS
AM-38 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnmTWM2OD1yLkKwPFQ5KM7:TR?= M3f2R3NCVkeHUh?=
A172 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLXPI9KSzVyPUCuNlExOjJizszN MkH5V2FPT0WU
HPAF-II NGXESmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7PN5RKSzVyPUCuNlEzPjRizszN MW\TRW5ITVJ?
769-P NH3zSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnTUFgxUUN3ME2wMlIyOjhizszN MYnTRW5ITVJ?
MFE-280 NV3Cemh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPITG5sUUN3ME2wMlIyOjl6IN88US=> MVvTRW5ITVJ?
TE-9 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[zTWM2OD1yLkKxO|g3KM7:TR?= NVTFZ5J6W0GQR1XS
C2BBe1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;BS|hRUUN3ME2wMlIzOTlizszN NFXzWVhUSU6JRWK=
EoL-1-cell MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fGTWlEPTB;MD6yNlIxOyEQvF2= NX\ESXRoW0GQR1XS
G-361 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnFUmNKSzVyPUCuNlI3QDJizszN NXPrfVlVW0GQR1XS
KYSE-270 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqxU|RKSzVyPUCuNlMxQDRizszN NHnaUVdUSU6JRWK=
TK10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy5PJRKSzVyPUCuNlMyOTdizszN MYHTRW5ITVJ?
ML-2 MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XDcWlEPTB;MD6yN|EyQSEQvF2= MkG1V2FPT0WU
MHH-ES-1 M3rtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMkO2PFEh|ryP M3jqXHNCVkeHUh?=
BHY M3TqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETjWFlKSzVyPUCuNlM3QTFizszN NH:4WIFUSU6JRWK=
LS-513 NX;mfVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLt[YlKSzVyPUCuNlM6PjFizszN MX3TRW5ITVJ?
COLO-678 M4SyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXQXYVkUUN3ME2wMlI1ODR2IN88US=> NFnSNm5USU6JRWK=
NCI-H747 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMkSxOlkh|ryP NUHTeZZUW0GQR1XS
K5 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXEO2FKSzVyPUCuNlQ{QCEQvF2= NWnHeoJZW0GQR1XS
OS-RC-2 NG[4fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfvXVRnUUN3ME2wMlI1PTB7IN88US=> NUXDUWJCW0GQR1XS
KINGS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu0SmJpUUN3ME2wMlI1PTJ7IN88US=> MXzTRW5ITVJ?
SCC-25 NVTLZXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXrTWM2OD1yLkK0OVY{KM7:TR?= M{ftRnNCVkeHUh?=
CAPAN-1 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMkS3PFMh|ryP MlHGV2FPT0WU
ESS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WwV2lEPTB;MD6yOFgxPSEQvF2= M2DnXnNCVkeHUh?=
TE-6 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL3TWM2OD1yLkK1O|Uh|ryP MU\TRW5ITVJ?
LB2518-MEL M3HEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfTdXZKUUN3ME2wMlI2Pzd5IN88US=> MXPTRW5ITVJ?
COLO-800 M2CzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMkW4NVIh|ryP NGq3SlBUSU6JRWK=
LU-134-A NHj1do9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHSTWM2OD1yLkK2NVM3KM7:TR?= MmC1V2FPT0WU
NCI-H1155 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMk[xOlIh|ryP MXXTRW5ITVJ?
MFM-223 NVzSOXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMk[zOlMh|ryP NVn5dIpIW0GQR1XS
HTC-C3 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD4TWM2OD1yLkK2OVA3KM7:TR?= MnvFV2FPT0WU
HCT-116 NWXmOVV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5[pExUUN3ME2wMlI3PTl7IN88US=> M1XM[HNCVkeHUh?=
Ca-Ski NXLPdXlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMk[2O|gh|ryP MYjTRW5ITVJ?
SBC-1 M4rWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\FWGlEPTB;MD6yOlc1OiEQvF2= NI\HNoNUSU6JRWK=
NB69 M4fPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMkewPFch|ryP NEPRT|NUSU6JRWK=
J82 NVfJTmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH4XFlKSzVyPUCuNlczPjVizszN M33sUHNCVkeHUh?=
U-118-MG NWTtfHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjiNG05UUN3ME2wMlI4PTd7IN88US=> NWLxWZVVW0GQR1XS
NCI-H1355 M1T3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH5TlVKSzVyPUCuNlgxPzRizszN MV7TRW5ITVJ?
NCI-H1048 Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD0dlJ7UUN3ME2wMlI5QTV4IN88US=> NYniRo46W0GQR1XS
SW954 NGD2fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMkmyNlch|ryP MVLTRW5ITVJ?
NMC-G1 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMkmyO|ch|ryP NGW5dmFUSU6JRWK=
SW1710 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMkm0PVQh|ryP MU\TRW5ITVJ?
KY821 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXGTW1vUUN3ME2wMlI6QDd{IN88US=> M{nhfXNCVkeHUh?=
HCC38 M3Pje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX6SnFKUUN3ME2wMlMxODd6IN88US=> MX\TRW5ITVJ?
NCI-SNU-5 M4izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLSZoJKSzVyPUCuN|A2PCEQvF2= M4LFUnNCVkeHUh?=
ES8 M1XjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwM{C3PFQh|ryP M3\OcHNCVkeHUh?=
COLO-792 NWfsSo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jmOmlEPTB;MD6zNVI2OSEQvF2= M3zQTHNCVkeHUh?=
BFTC-905 MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwM{G1NlEh|ryP MUTTRW5ITVJ?
ChaGo-K-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqwZXBKSzVyPUCuN|E4OTVizszN M2C0eHNCVkeHUh?=
Daoy MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmwTWM2OD1yLkOxO|I{KM7:TR?= MVTTRW5ITVJ?
SJSA-1 NHnHN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LoNWlEPTB;MD6zNVg1PyEQvF2= MX\TRW5ITVJ?
KNS-62 MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwM{KwPFgh|ryP NXn4VVZoW0GQR1XS
CAKI-1 M3;VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLhdYVMUUN3ME2wMlMzOTFzIN88US=> M2XIV3NCVkeHUh?=
UACC-62 M1vrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHRTWM2OD1yLkOyNlI4KM7:TR?= NGCxbldUSU6JRWK=
HuCCT1 NHvBWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX74SFhuUUN3ME2wMlMzOjh|IN88US=> MYnTRW5ITVJ?
CTB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwM{K3OVMh|ryP MmG5V2FPT0WU
NTERA-S-cl-D1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPRTWM2OD1yLkOyPFM3KM7:TR?= NWHxSphPW0GQR1XS
T-24 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\IWGlEPTB;MD6zN|E2QSEQvF2= NX\iUZFPW0GQR1XS
KYSE-70 NXPWeollT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwM{OyPFMh|ryP NH74b5JUSU6JRWK=
SW626 NUPE[lB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwM{O1N|Ih|ryP M37pfnNCVkeHUh?=
LB996-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom2TWM2OD1yLkOzOlE6KM7:TR?= MmTpV2FPT0WU
DMS-273 NWPEWpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHQeYJKSzVyPUCuN|M6OTZizszN M12wcHNCVkeHUh?=
SW1783 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzmTG96UUN3ME2wMlM{QTl5IN88US=> MljvV2FPT0WU
KU812 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDBTWM2OD1yLkO0NFM5KM7:TR?= NFnsSFZUSU6JRWK=
HSC-2 NEn5VHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTKTZprUUN3ME2wMlM1ODV|IN88US=> MXLTRW5ITVJ?
A3-KAW MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuwOot6UUN3ME2wMlM1OTZ{IN88US=> NGHsUFZUSU6JRWK=
COLO-684 M4rsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwM{S1NFEh|ryP NV\xPHhPW0GQR1XS
NCI-H2405 NIL2PGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\mcI5KSzVyPUCuN|Q3OzFizszN NWXXOFhUW0GQR1XS
NCI-H2228 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzFTWM2OD1yLkO1N|U4KM7:TR?= NGPXNnpUSU6JRWK=
NB13 NV3sS29pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPSSnBZUUN3ME2wMlM3QDJ7IN88US=> NX7TNoJjW0GQR1XS
no-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PiSmlEPTB;MD6zOlk2KM7:TR?= M3PUSXNCVkeHUh?=
DK-MG NGPrWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\kemlEPTB;MD6zO|E5QCEQvF2= NYr4S3V4W0GQR1XS
NBsusSR MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjsZmVyUUN3ME2wMlM4Ojh3IN88US=> NH7IdVZUSU6JRWK=
KP-N-YS NHj6U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjaZ4V{UUN3ME2wMlM4PDZ|IN88US=> M1;EVXNCVkeHUh?=
CFPAC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXqNIpKSzVyPUCuN|c2OThizszN NHzwO|lUSU6JRWK=
KARPAS-45 NWTqTXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDoWIVCUUN3ME2wMlM4QDZ{IN88US=> NFvkZ2hUSU6JRWK=
NCI-H1793 NHTHeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwM{i1NUDPxE1? NVTHRmh5W0GQR1XS
HCE-T MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rHRmlEPTB;MD6zPFYxOyEQvF2= NVT5S|dbW0GQR1XS
NCI-H520 NWHtRVhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwM{i3NFMh|ryP NX73WlFuW0GQR1XS
HCC2157 M{PBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwM{i3PFEh|ryP NU\oZ3ByW0GQR1XS
EW-18 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzMU|lKSzVyPUCuN|g6PDFizszN M4TtVnNCVkeHUh?=
RO82-W-1 NYjHdpNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwM{m2PVkh|ryP MXHTRW5ITVJ?
HuP-T3 NHrNV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13QV2lEPTB;MD60NFE1OyEQvF2= MoCwV2FPT0WU
PANC-10-05 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDTTWM2OD1yLkSxNVch|ryP NHHyTlBUSU6JRWK=
NCI-H1703 M3ztW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorqTWM2OD1yLkSxOFQ3KM7:TR?= NFXUWoxUSU6JRWK=
TE-10 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjrVnltUUN3ME2wMlQyPDR5IN88US=> NHXuRohUSU6JRWK=
HOS M3XQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPkTXZKSzVyPUCuOFE3QDJizszN NGPNUWhUSU6JRWK=
LN-405 NEXTVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv3[WZKSzVyPUCuOFE3QDdizszN M{nhd3NCVkeHUh?=
A427 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfvTWM2OD1yLkSxPVgyKM7:TR?= MlTYV2FPT0WU
CAL-12T Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Sy[WlEPTB;MD60Nlc5KM7:TR?= M1POVHNCVkeHUh?=
SW756 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfzR2VKSzVyPUCuOFQyQDNizszN Ml[2V2FPT0WU
YAPC M3foXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHERlVRUUN3ME2wMlQ2ODhizszN NIXPWZpUSU6JRWK=
GOTO NFLhSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjSS5kzUUN3ME2wMlQ2OTZizszN NXrlblV{W0GQR1XS
C3A NIS3[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGmzZXZKSzVyPUCuOFU1OzdizszN MYjTRW5ITVJ?
UM-UC-3 NGq0N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\idmlEPTB;MD60OVQ4KM7:TR?= MUHTRW5ITVJ?
NCI-H1573 MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlntTWM2OD1yLkS1OVY6KM7:TR?= MU\TRW5ITVJ?
LS-411N NE\DVnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXuTWM2OD1yLkS2OVI4KM7:TR?= M1HRS3NCVkeHUh?=
COR-L23 NHrld2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4TWM2OD1yLkS2O|Y1KM7:TR?= NI\IU5dUSU6JRWK=
HCE-4 NXnqUIFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwNEe0OFYh|ryP NX3p[48zW0GQR1XS
NCI-H2291 NVnMS2Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PpbWlEPTB;MD60O|g6PiEQvF2= MWXTRW5ITVJ?
A101D NIrYTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe3OIlKSzVyPUCuOFgxPTNizszN MX;TRW5ITVJ?
HT-3 NWLrcnhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm1TWM2OD1yLkS4NlE4KM7:TR?= M2nFdXNCVkeHUh?=
HOP-62 NXXpXHg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwNEm4OlUh|ryP Mo[5V2FPT0WU
PC-3 M3zwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXmV4ZKSzVyPUCuOVE2ODdizszN NF7tXFZUSU6JRWK=
CTV-1 NVXpO5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLMTWM2OD1yLkWyOlY6KM7:TR?= MkXrV2FPT0WU
PANC-08-13 M1T0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rLbmlEPTB;MD61N|E4PyEQvF2= M3e4VnNCVkeHUh?=
CAL-120 M1Kydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD1yLkWzN|k6KM7:TR?= MnOxV2FPT0WU
UMC-11 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\mTWM2OD1yLkW1NlM1KM7:TR?= MnrkV2FPT0WU
MSTO-211H NGf1PY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDxd5lKSzVyPUCuOVU4PjJizszN NHO2Z4dUSU6JRWK=
NCI-H2126 NFv1ZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjkd5RKSzVyPUCuOVY5OTVizszN NFPTdlhUSU6JRWK=
SNU-C2B NGnyRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPhbXBKSzVyPUCuOVc6PzdizszN MoHhV2FPT0WU
DBTRG-05MG NWTaUHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nSV2lEPTB;MD61PFA2OyEQvF2= M4XaSXNCVkeHUh?=
MKN1 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwNUi3PFMh|ryP NIC2c5pUSU6JRWK=
ES3 M3rqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmryTWM2OD1yLkW5NVI1KM7:TR?= Mnj6V2FPT0WU
OVCAR-3 NFLxR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGzO5R7UUN3ME2wMlU6OzRzIN88US=> MWHTRW5ITVJ?
ACHN MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNkC1Olkh|ryP MXXTRW5ITVJ?
SW872 MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNkC3OlMh|ryP M1;UOXNCVkeHUh?=
CP66-MEL NI\acmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXwdJRKSzVyPUCuOlA6PjlizszN NYXwfGd4W0GQR1XS
NCI-H661 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNkGxNFQh|ryP MlnOV2FPT0WU
UACC-893 NUjIb5NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrGTWM2OD1yLk[zOlgyKM7:TR?= MVPTRW5ITVJ?
JVM-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OycmlEPTB;MD62N|gxPCEQvF2= NUjXUYp3W0GQR1XS
SF268 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fDRmlEPTB;MD62OFM1QSEQvF2= MXXTRW5ITVJ?
OCI-AML2 NY\DeGJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz5TWM2OD1yLk[1N|k4KM7:TR?= M4nUXHNCVkeHUh?=
RPMI-8226 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXlTWM2OD1yLk[2N|I{KM7:TR?= NELyVmVUSU6JRWK=
MKN28 M1j4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHUe5U6UUN3ME2wMlY3PjJ2IN88US=> NXjneJZ7W0GQR1XS
MDA-MB-453 NGTwOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTPWmZKSzVyPUCuOlcyQCEQvF2= MWjTRW5ITVJ?
BV-173 NH;u[|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lk[2lEPTB;MD62PFY4QSEQvF2= MUPTRW5ITVJ?
NCI-H358 M3fYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnnTWZOUUN3ME2wMlY5PzJ4IN88US=> M1\ROnNCVkeHUh?=
NCI-H1651 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13YbWlEPTB;MD63JO69VQ>? NVO1ZWxuW0GQR1XS
MDA-MB-415 NWTqWIFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\DeGtKSzVyPUCuO|A5OjlizszN NYXiVGZrW0GQR1XS
8305C NXmyXpNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwN{K0PVgh|ryP M3i4NnNCVkeHUh?=
EFM-19 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\HN4hrUUN3ME2wMlc{PjdzIN88US=> MonsV2FPT0WU
RERF-LC-MS M2D4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwN{S2NVMh|ryP M4OwW3NCVkeHUh?=
A388 MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrrTWM2OD1yLke2OFY4KM7:TR?= M2TSUnNCVkeHUh?=
GI-ME-N NWHIflVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n6dGlEPTB;MD63O|I{PSEQvF2= Mle5V2FPT0WU
IGR-1 NWTFXYpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\BV3RKSzVyPUCuO|kxPDNizszN M33RSHNCVkeHUh?=
LNCaP-Clone-FGC M4TGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjhUo5KSzVyPUCuPFAxODRizszN NV:3bnM2W0GQR1XS
SK-MEL-3 NELo[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjXTWM2OD1yLkixOVA5KM7:TR?= MlXIV2FPT0WU
UACC-257 M{HOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPmXXFuUUN3ME2wMlgzOjNzIN88US=> MmjpV2FPT0WU
OE33 NVnTZYF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\yTnhKSzVyPUCuPFUyODFizszN NEnXUFFUSU6JRWK=
QIMR-WIL NGfrcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DOWmlEPTB;MD64OVE1OSEQvF2= NF;md3RUSU6JRWK=
NCI-H2009 M4Dk[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;NTWM2OD1yLki1N|EyKM7:TR?= NUG1RpN7W0GQR1XS
NCI-H522 NWDIXmlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\wcW5KSzVyPUCuPFc4QDNizszN MW\TRW5ITVJ?
Saos-2 NHjkPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTK[|Z7UUN3ME2wMlg4QDdzIN88US=> NXu2dnhyW0GQR1XS
NB17 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwOEiwNlUh|ryP NHW4S2FUSU6JRWK=
D-392MG NWrpZm9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7FT5lKSzVyPUCuPFk{PTZizszN M4XQWnNCVkeHUh?=
SHP-77 M1;PRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX6TWM2OD1yLkmwOFg2KM7:TR?= NUDvSINOW0GQR1XS
SK-MEL-30 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrNTWM2OD1yLkmxNVg2KM7:TR?= NFP0ZXJUSU6JRWK=
GCIY M{fJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\VTWM2OD1yLkmxPFQ{KM7:TR?= MnPnV2FPT0WU
HCC70 NVTSR3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwOUKwOVkh|ryP NVi1U4txW0GQR1XS
LU-65 M4HBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS2TWM2OD1yLkmyOVkyKM7:TR?= NWLpO5RZW0GQR1XS
NCI-H1563 NFy0SmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuySZpKSzVyPUCuPVQ5PjVizszN MYTTRW5ITVJ?
KURAMOCHI MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe1R2F4UUN3ME2wMlk2OTl{IN88US=> MWrTRW5ITVJ?
PA-1 M13JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ROm1KSzVyPUCuPVU1OjRizszN M3;DbHNCVkeHUh?=
NOS-1 NU\tPIRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fRXGlEPTB;MD65O|Q5QSEQvF2= MUfTRW5ITVJ?
NCI-H69 NI\yTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfqNldKSzVyPUCuPVc3OzRizszN NXP0eGtZW0GQR1XS
KYSE-450 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG5UZNiUUN3ME2wMlk5PjJ4IN88US=> NWXsOZo{W0GQR1XS
8505C NVjvWVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\WVHFKSzVyPUCuPVk6QDJizszN MVrTRW5ITVJ?
TGBC24TKB NUnVeYw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXHfHhKSzVyPUGuNFAxQDRizszN MkDrV2FPT0WU
PFSK-1 NVHpVlg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTFwMEG0Nlgh|ryP MnexV2FPT0WU
EKVX NEXEV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DBT2lEPTB;MT6wN|EzOSEQvF2= NGDHbHpUSU6JRWK=
RCM-1 NInCXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjCTWM2OD1zLkC1OVA4KM7:TR?= M1XPcnNCVkeHUh?=
SW900 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTFTWM2OD1zLkC3PFMh|ryP NYfYdZVwW0GQR1XS
D-542MG M13BS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnWSJh2UUN3ME2xMlA4QDV3IN88US=> NFrTVZdUSU6JRWK=
SK-PN-DW M1HJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\u[mplUUN3ME2xMlExODV4IN88US=> M4m1VHNCVkeHUh?=
NCI-H727 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn6SpV3UUN3ME2xMlExOTV2IN88US=> MV3TRW5ITVJ?
SW837 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwMUC5OVQh|ryP M{nvOnNCVkeHUh?=
BT-20 NVT3O41mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwMUGyNFQh|ryP NXXNfmxQW0GQR1XS
RH-18 NVuwXnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwMUOxNFMh|ryP MW\TRW5ITVJ?
TE-12 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrYe3JKSzVyPUGuNVM{OzNizszN NXywPWw1W0GQR1XS
NB10 NWO4[Fd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTFwMUOzOFQh|ryP Moi1V2FPT0WU
AU565 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknpTWM2OD1zLkG1PVc{KM7:TR?= NYLyXlJ3W0GQR1XS
OAW-42 NHvrdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PMTGlEPTB;MT6xPFMxPiEQvF2= MlztV2FPT0WU
DJM-1 NWDMRWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXCOnRKSzVyPUGuNVk5QDFizszN MlO3V2FPT0WU
HH M3XvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHoc4oxUUN3ME2xMlI{QDNzIN88US=> NETP[ndUSU6JRWK=
LAMA-84 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILsb5NKSzVyPUGuNlc{QTRizszN MYfTRW5ITVJ?
KNS-42 NUXObY5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwM{CyPVYh|ryP NV7oXY01W0GQR1XS
NCI-H2052 NXL4e4syT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfGTWM2OD1zLkOwOVA4KM7:TR?= M2\YSHNCVkeHUh?=
MLMA NIPRdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrmeFNUUUN3ME2xMlMzPDB5IN88US=> MoT0V2FPT0WU
NB12 MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\JTWM2OD1zLkO1OlM3KM7:TR?= NETnNmJUSU6JRWK=
NCI-H1838 NWjJdo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTTfpd6UUN3ME2xMlM3OzB4IN88US=> NFvYco9USU6JRWK=
NCI-H526 NYTON3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjDR3NKSzVyPUGuN|c5PTNizszN NEH0R|BUSU6JRWK=
LS-123 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXqTnF3UUN3ME2xMlM6ODl2IN88US=> MoHhV2FPT0WU
HDLM-2 M2TDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fIVmlEPTB;MT6zPVI4OSEQvF2= NHP6dodUSU6JRWK=
MC-IXC MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVWyU25LUUN3ME2xMlQzOzdzIN88US=> MYnTRW5ITVJ?
HCT-15 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzNTWM2OD1zLkSzNFY5KM7:TR?= NUjHVW9YW0GQR1XS
NCI-H596 NHSycnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GzR2lEPTB;MT60OVA3OSEQvF2= MVXTRW5ITVJ?
ZR-75-30 NV7JVJJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjYTWM2OD1zLkS3NFgzKM7:TR?= MonxV2FPT0WU
A704 NV[yWoFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwNk[1OlMh|ryP MVPTRW5ITVJ?
OVCAR-4 M3jrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnztTWM2OD1zLk[5OlA4KM7:TR?= MmK0V2FPT0WU
SW1417 NHTVeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjqS4xwUUN3ME2xMlczQDR7IN88US=> MXXTRW5ITVJ?
CAS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwN{O5N|Yh|ryP MlLlV2FPT0WU
IST-SL1 M1zGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTIXI9KSzVyPUGuO|k4PTlizszN NIHNTpdUSU6JRWK=
A253 NIO3NIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX0TWM2OD1zLkiyNlM6KM7:TR?= NFfFc2RUSU6JRWK=
EW-16 NV\WdY1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFwOEK4O|Uh|ryP MljoV2FPT0WU
SK-NEP-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwOE[5PFgh|ryP MXrTRW5ITVJ?
NCI-H226 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzaTWM2OD1zLki5N|U6KM7:TR?= NU\OR|QyW0GQR1XS
HOP-92 NETpbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[0TWM2OD1zLkm2NFk6KM7:TR?= NGiwVJNUSU6JRWK=
NCI-H441 NH3ne25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTq[IIxUUN3ME2yMlAzOzN5IN88US=> NEL3WVNUSU6JRWK=
LU-139 M3rFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwMEOxNVQh|ryP NFnBVZhUSU6JRWK=
SJRH30 M37XRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL4UHMxUUN3ME2yMlA1OjV|IN88US=> MVjTRW5ITVJ?
MG-63 NGflUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\nXoY3UUN3ME2yMlE1OTFzIN88US=> MUjTRW5ITVJ?
NH-12 NHP6U49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJwMUWwNFYh|ryP M1fFSnNCVkeHUh?=
NB7 NGn4RWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMUm2O|Mh|ryP NYfpNJhvW0GQR1XS
LB771-HNC M1TYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;OTWM2OD1{LkKwOVk2KM7:TR?= MVjTRW5ITVJ?
HCC1569 NFrXclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn6W4FKSzVyPUKuNlQ2QDNizszN MUXTRW5ITVJ?
D-283MED MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X0ZWlEPTB;Mj6yOFc5OiEQvF2= MknEV2FPT0WU
J-RT3-T3-5 M3Sxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjFTHVYUUN3ME2yMlI2OzVzIN88US=> M2\rNnNCVkeHUh?=
ATN-1 MorvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\4N2pEUUN3ME2yMlM{ODh{IN88US=> MnLFV2FPT0WU
HCC1954 M1jXOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwM{S0NFgh|ryP MXjTRW5ITVJ?
SCC-15 M3rq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDTTWM2OD1{LkO5N|EzKM7:TR?= NEXqRYVUSU6JRWK=
COLO-668 MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfFPYxKSzVyPUKuOFMzKM7:TR?= M1PJcXNCVkeHUh?=
LB373-MEL-D NG[3XnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorQTWM2OD1{LkW0Olc4KM7:TR?= MWDTRW5ITVJ?
no-10 NYP5TlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XIZ2lEPTB;Mj61OFk1PyEQvF2= NF76dHRUSU6JRWK=
HT-1197 M2rYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJwNkOxPFgh|ryP M173WnNCVkeHUh?=
DU-145 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYixOWpOUUN3ME2yMlc6OTZ{IN88US=> NF7mcmdUSU6JRWK=
SK-N-AS M{jhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHXbHlKSzVyPUKuPFQ3QTJizszN MXvTRW5ITVJ?
MOLT-4 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrBOldKSzVyPUKuPFU{OjJizszN M4q0dnNCVkeHUh?=
EW-22 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXGTWM2OD1{LkmyPFQyKM7:TR?= M{HXUHNCVkeHUh?=
DB MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\E[5VDUUN3ME2yMlk4PzV7IN88US=> MX7TRW5ITVJ?
HL-60 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP0TYJKSzVyPUOuNFQ{PzZizszN M2H6[3NCVkeHUh?=
SK-N-DZ MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO3TWM2OD1|LkC1NFc2KM7:TR?= M4n3RXNCVkeHUh?=
NY Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\jNlBqUUN3ME2zMlA5PTR{IN88US=> M4Wxc3NCVkeHUh?=
T47D NYHoSVhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnCNIxKSzVyPUOuNVA2PThizszN M{juTnNCVkeHUh?=
NCI-H2029 M3PCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ofJdKSzVyPUOuNlI1PzdizszN NUTJTGdGW0GQR1XS
KARPAS-299 M1vrdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XVTmlEPTB;Mz6yOlAzPyEQvF2= NV\4TlZCW0GQR1XS
KM-H2 NU\SO2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\SXJZ6UUN3ME2zMlMxPjhizszN M2K0fnNCVkeHUh?=
CHP-134 NIryeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInTdZlKSzVyPUOuOFc{QSEQvF2= MWjTRW5ITVJ?
22RV1 M2rkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf5elNLUUN3ME2zMlQ6OTZ6IN88US=> Ml7ZV2FPT0WU
NB5 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q4RWlEPTB;Mz61NFY5QSEQvF2= MmfSV2FPT0WU
CW-2 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu4TWM2OD1|LkW1N|E1KM7:TR?= M1v0S3NCVkeHUh?=
EFO-21 MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwNU[5OEDPxE1? NXTEc2RXW0GQR1XS
HuH-7 M{niXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDQTWM2OD1|LkW4OFE1KM7:TR?= NX7nU3FuW0GQR1XS
ALL-PO NFm2c|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TifWlEPTB;Mz62NlM{PSEQvF2= NWi3UoZnW0GQR1XS
EM-2 NWCz[JBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrjeWRKSzVyPUOuOlkxOTFizszN MWPTRW5ITVJ?
KLE M{XHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrxZnBKSzVyPUOuO|MxOjlizszN NUfFU3NCW0GQR1XS
NEC8 NGHHfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTNwOUG4NFgh|ryP M3fMOXNCVkeHUh?=
KP-N-YN NYHlb4xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwOUO0O|Yh|ryP MX;TRW5ITVJ?
SK-MEL-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzQTWM2OD12LkCzOVE5KM7:TR?= MXPTRW5ITVJ?
CAL-54 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MontTWM2OD12LkC1PVEh|ryP MUnTRW5ITVJ?
MS-1 NGLyOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfBb2hkUUN3ME20MlE3OTV3IN88US=> MmGyV2FPT0WU
NCI-H209 M2fBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jKVWlEPTB;ND6yPVk6QSEQvF2= Mn;iV2FPT0WU
NOMO-1 NUj4SGd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\STWM2OD12LkOyNVMyKM7:TR?= MV7TRW5ITVJ?
RPMI-2650 NH3ZTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzkTWM2OD12LkO2N|I4KM7:TR?= MW\TRW5ITVJ?
NCI-H810 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSTWM2OD12LkO5O|M3KM7:TR?= M4GwS3NCVkeHUh?=
Ca9-22 NGLJO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTRwNEW2PVEh|ryP M3XRRXNCVkeHUh?=
ES4 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPDTWM2OD12LkS3NFk2KM7:TR?= M4TobHNCVkeHUh?=
ES6 NVu0ZVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nVdmlEPTB;ND60PVY2PyEQvF2= NH;sRohUSU6JRWK=
DMS-114 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTRwNUS2PVEh|ryP NVjxNnY2W0GQR1XS
ONS-76 M1;OPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUToRXZ7UUN3ME20MlU4QTVizszN MXPTRW5ITVJ?
K-562 NH3jeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwN{O4NVQh|ryP MYDTRW5ITVJ?
MHH-NB-11 M2jrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRwN{W0OlEh|ryP NEXWUWpUSU6JRWK=
Calu-3 NHnP[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYU5JKSzVyPUSuO|g2PDhizszN MlrnV2FPT0WU
HT55 NU\zZVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nRemlEPTB;ND64OFU1PSEQvF2= MoDMV2FPT0WU
SK-N-FI Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\LTWM2OD12Lki1NFA6KM7:TR?= MmnTV2FPT0WU
ES1 MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRwOE[wOVch|ryP MX\TRW5ITVJ?
SF126 MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17Ue2lEPTB;ND65N|E5PCEQvF2= NFyyRXRUSU6JRWK=
ES5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVwMUK0Nlch|ryP MmW0V2FPT0WU
LoVo M4CxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpXmlEPTB;NT6xOVg4OSEQvF2= NYLOcodWW0GQR1XS
SNU-387 Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTVwM{KzN|kh|ryP NYjaUJlnW0GQR1XS
C8166 NX7xcoRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTVwM{[zN|kh|ryP NV23cWoyW0GQR1XS
LS-1034 NEHER3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHrTnhKSzVyPUWuOFI{ODdizszN NF3iOolUSU6JRWK=
GR-ST MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jtd2lEPTB;NT61NlIxOSEQvF2= Ml6zV2FPT0WU
NCI-H1092 NEDaUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17COGlEPTB;NT63Nlg1OyEQvF2= M3;MSHNCVkeHUh?=
647-V NXuz[5FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXH2OmI3UUN3ME21Mlc1PzB4IN88US=> NGH4eYZUSU6JRWK=
EW-13 Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLTTWM2OD13Lke2OlI4KM7:TR?= MlPSV2FPT0WU
KGN MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjQRmxKSzVyPU[uNFk6OjFizszN NIjnNnZUSU6JRWK=
D-423MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPhTWM2OD14LkSwNlg1KM7:TR?= NELl[YRUSU6JRWK=
ECC10 M{XDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLTTWM2OD15LkGwNVAyKM7:TR?= NHTMbotUSU6JRWK=
TE-5 M3HtdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH71boNKSzVyPUeuOFEzQThizszN NXzBUo1SW0GQR1XS
P12-ICHIKAWA NH7sfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3zXpNKSzVyPUeuOFU2OjNizszN MX3TRW5ITVJ?
NCI-H82 NFK3XoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nGcWlEPTB;Nz60OVcxOSEQvF2= MV\TRW5ITVJ?
NCI-H1993 M{n2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PoWmlEPTB;Nz64N|A3OyEQvF2= M37UWXNCVkeHUh?=
RH-1 NHrJV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HEOmlEPTB;Nz64OVI1PCEQvF2= NUjJb|U3W0GQR1XS
SW948 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;R[IljUUN3ME23Mlk3ODR7IN88US=> MVjTRW5ITVJ?
CAL-33 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XrN2lEPTB;Nz65PVk{QCEQvF2= NWT1cJdPW0GQR1XS
U-266 M4ew[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRThwMUW3O|ch|ryP M{XIVXNCVkeHUh?=
CAL-72 M4S1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRThwMkCzNkDPxE1? NF6wVYtUSU6JRWK=
SNU-423 M4TM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjvTWM2OD17LkO2OlY3KM7:TR?= NHrScJZUSU6JRWK=
KG-1 M1;6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yZ3BnUUN3ME25MlU5PDV4IN88US=> NI\1cldUSU6JRWK=
HCC1395 M1zDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPhTnh[UUN3ME25MlkzOzV{IN88US=> MmTwV2FPT0WU
BE-13 M1;6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTzTWM2OD1zMD64PFkzKM7:TR?= MUfTRW5ITVJ?
MKN7 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vlSmlEPTB;MUCuPVc3PSEQvF2= NEHlNIdUSU6JRWK=
697 NW\RWpFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPve|lKSzVyPUGxMlE1PzJizszN NHzCcG5USU6JRWK=
LU-135 NHLE[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFzLkKzNFch|ryP M3LqSnNCVkeHUh?=
ES7 M2DpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm5UGRKSzVyPUGxMlM{OTNizszN MlvVV2FPT0WU
SK-HEP-1 NFjPfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFzLke2OFYh|ryP NG\aPIlUSU6JRWK=
BEN M4nBTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnmSYVlUUN3ME2xNU45PTFizszN MoHqV2FPT0WU
NCI-H1770 NXjVcHJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrXeGlKSzVyPUGyMlEzPiEQvF2= M{\Nb3NCVkeHUh?=
SW13 NVL5RmdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF{LkG1OFEh|ryP NFe0TXFUSU6JRWK=
MZ1-PC MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe0TWM2OD1zMj61OFUzKM7:TR?= MkHRV2FPT0WU
Mo-T M1TEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLHTWM2OD1zMj63OFIyKM7:TR?= M{jtN3NCVkeHUh?=
HLE MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF{LkiyNVUh|ryP NH74TIFUSU6JRWK=
RCC10RGB M2rBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnzbI0{UUN3ME2xN{43PzFizszN MlPzV2FPT0WU
COLO-320-HSR M2nUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LZ[GlEPTB;MUOuO|M5OSEQvF2= M2H0O3NCVkeHUh?=
BHT-101 NF3GWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV31U|hEUUN3ME2xN{45OzR3IN88US=> M2TP[nNCVkeHUh?=
OCUB-M MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fSeWlEPTB;MUSuNVYxOiEQvF2= NUfwTY9bW0GQR1XS
MEG-01 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOzZZNiUUN3ME2xOE4{PzB6IN88US=> MX;TRW5ITVJ?
RS4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXQdJZNUUN3ME2xOE44PDJizszN MUDTRW5ITVJ?
MN-60 MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[xTWM2OD1zND63PFk1KM7:TR?= NHTKW|lUSU6JRWK=
NCI-H1304 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XwfWlEPTB;MUWuNFQzPSEQvF2= MWXTRW5ITVJ?
Ramos-2G6-4C10 NWPMcZUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rXcmlEPTB;MUWuNFU5OSEQvF2= Mo\PV2FPT0WU
NCI-H2342 NEHqVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDvTWM2OD1zNT6yNFQ1KM7:TR?= M3LUOnNCVkeHUh?=
LAN-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXoOJJKSzVyPUG1MlQ1OTRizszN Ml;1V2FPT0WU
JVM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF3LkW3OFgh|ryP NFvJXXpUSU6JRWK=
P30-OHK NF:wTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjNdWZKSzVyPUG2MlA3OTRizszN M1PHeHNCVkeHUh?=
C-33-A M2n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPpTWM2OD1zNj62NlE1KM7:TR?= NUG0XI46W0GQR1XS
RPMI-8866 NELsUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LFb2lEPTB;MU[uPFQ6PiEQvF2= MnW3V2FPT0WU
NCI-H630 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF4Lki1N|ch|ryP MVTTRW5ITVJ?
KYSE-140 NHHnPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PZW2lEPTB;MUeuNlAzQCEQvF2= NV\DUWhwW0GQR1XS
T84 NHL2bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHTTWM2OD1zOD64Olk2KM7:TR?= NV7keI9yW0GQR1XS
KU-19-19 NXvCSnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULjTllmUUN3ME2xPE46PjB6IN88US=> MXjTRW5ITVJ?
BALL-1 M2HRUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PDPGlEPTB;MUmuN|M6QSEQvF2= M4rpfXNCVkeHUh?=
Calu-6 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rme2lEPTB;MUmuOFkzKM7:TR?= M3exfXNCVkeHUh?=
EGI-1 NXHNTZo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PoPWlEPTB;MUmuOVk5KM7:TR?= M1HQdXNCVkeHUh?=
MFH-ino NEXZOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fyOGlEPTB;MUmuO|Q2PCEQvF2= MkLqV2FPT0WU
GB-1 NWLwWIROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJyLkO1N|Uh|ryP NEHKfHBUSU6JRWK=
NCI-H1693 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTJPGxKSzVyPUKwMlY2ODVizszN M1fUSXNCVkeHUh?=
SW1116 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWS2UZJCUUN3ME2yNE46OzZ{IN88US=> NE\WPI1USU6JRWK=
H-EMC-SS NXOyUI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLtTWM2OD1{Mj6wOFUh|ryP M3rTWXNCVkeHUh?=
D-502MG Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHoXIdNUUN3ME2yNk45OjZzIN88US=> MljnV2FPT0WU
IA-LM M1jaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ|LkK0PVMh|ryP MoexV2FPT0WU
SW1463 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTJ|Lke5JO69VQ>? MnnPV2FPT0WU
JAR NXfZNmd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LnTWlEPTB;MkSuN|I6OyEQvF2= M2Hac3NCVkeHUh?=
HT NInxN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPYTGRKSzVyPUK0MlQ4PTNizszN NF\KW5NUSU6JRWK=
LCLC-103H MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Bc2lEPTB;MkSuPFQ1QSEQvF2= NVLxT5prW0GQR1XS
SNU-449 M4\T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ2Lki3OFEh|ryP M{GzZnNCVkeHUh?=
KE-37 NH:yVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS3WnIzUUN3ME2yOU4xQTJ6IN88US=> MXPTRW5ITVJ?
NCI-H1623 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjYTWM2OD1{Nz6xN|A{KM7:TR?= MlzLV2FPT0WU
MOLT-13 M1;uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7WTWM2OD1{Nz6zOVE3KM7:TR?= NYHzPGJpW0GQR1XS
COLO-741 M1TjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNzLkOzN|Mh|ryP M1[z[XNCVkeHUh?=
NB6 NUjQcG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHiTWM2OD1|Mj6yPFc3KM7:TR?= NXLlRW56W0GQR1XS
MOLT-16 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr5TWM2OD1|Mz6wNFU2KM7:TR?= NH\aNIJUSU6JRWK=
IST-MES1 NYLXV4dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfVfpJ7UUN3ME2zOE4xPTRzIN88US=> NXPoPWk1W0GQR1XS
A4-Fuk NWLrcWoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf0SmlEUUN3ME2zOU4xPjZizszN M{n6c3NCVkeHUh?=
CAL-85-1 NG[4eXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj6Slh3UUN3ME2zOU4zQDF5IN88US=> MlTlV2FPT0WU
CCRF-CEM MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL5fnJLUUN3ME2zO{4yPTN4IN88US=> M2jtR3NCVkeHUh?=
HAL-01 NVPL[411T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jlSmlEPTB;M{iuOFg5QSEQvF2= MUDTRW5ITVJ?
HEL MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR|LkO0NFkh|ryP NFLoToZUSU6JRWK=
EW-1 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknLTWM2OD12Mz60O|Y5KM7:TR?= NWnIRVhwW0GQR1XS
MDA-MB-231 NVe5U444T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TXXWlEPTB;NEWuNVE6QSEQvF2= MkjJV2FPT0WU
ABC-1 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TTPGlEPTB;NE[uPFU{QCEQvF2= Ml7YV2FPT0WU
NCI-H446 M4HvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTR6LkWwOVgh|ryP NF\S[JdUSU6JRWK=
MHH-PREB-1 NFHXfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR7Lk[wNFch|ryP MYrTRW5ITVJ?
DOHH-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nGW2lEPTB;NEmuOlY2PiEQvF2= NYj4WGczW0GQR1XS
GCT Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTR7Lk[5O|Yh|ryP M4LXZXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID